A16z-Backed Braveheart Biotech Seeks $318.8 Million in US IPO
A16z-backed Braveheart seeks $318.8 million in a US IPO, signaling continued vigor in the venture-backed biotech market.
A16z-backed Braveheart seeks $318.8 million in a US IPO, signaling continued vigor in the venture-backed biotech market.
ARK Invest’s research director counters a16z’s claim that traditional finance prefers permissioned blockchains, arguing institutional capital will flow into decentralized finance protocols.
Backed by $140M a16z funding, the crypto startup formerly Story Protocol is rebranding to create a blockchain audit layer for AI data…
Illinois enacts a novel crypto transaction tax, drawing ire from a16z's Miles Jennings, who highlighted that no state imposes similar taxes on…
Morpho's $175 million funding from a16z, Paradigm, and Ribbit aims to establish the protocol as a backbone for on-chain credit markets, boosting…